SARMS or selective androgen receptor modulators are well-known for giving the same muscle growth results as anabolic steroids but without the negative side effects that comes with the latter. Japanese scientists are doing an experiment on a new SARM known as YK11 which is said to be the strongest among them all.
YK11 is believed to be a SARM and produce the effect of myostatin at the same time.
Here’s what we know as of today…
In 2011, Yuichiro Kanno of Toho University published the results of an initial study on YK11, confirming that the rare compound was a SARM. However, most people are now considering it to be what’s called a Myostatin Inhibitor.
YK11 attaches itself to the AR (androgen receptor), and modulates specific muscle receptors while being able to eliminate the traditional effects of steroids.
Most SARMS have limited androgenic side effects, but also lesser anabolic effect when compared to testosterone.
However, that’s not the case with YK 11 according to the Biological and Pharmaceutical Bulletin in 2013. When Kanno used C2C12 muscle cells to test the effects of the SARM, it was found that the muscle cells produce more anabolic factors if exposed to 500 nmol (nanomoles) YK11 than if you expose the same muscle cells to 500 nmol DHT.
YK11 induces muscle cells to make even more follistatin than DHT does (a strong myostatin inhibitor). By working through the androgen receptor, YK 11 is able to product effects just as powerful as testosterone.
Most people recommend between 2 and 5 mg, twice per day. As anything else, always start low to assess tolerance and build your way up.
YK 11 is a powerful SARM that shouldn’t be taken lightly. However, even at 30mg people have reportedly felt little to no side effects.
YK11 shows a lot of promise as a very powerful muscle building SARM. It’s one of the newer SARMs currently undergoing research, but it looks incredibly promising.
As a myostatin inhibitor, it will also be amazing when combined with other SARMs. The only downside as people have mentioned are the fact that it’s never been done on human or animal trials at this point.
There’s still a lot to be learned, so our opinion on this SARM will change as more research develops.